Clinical trials: Phase I
Multiple System Atrophy
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)
The study purpose is conducting follow-up surveillance for the incidence of adverse events and efficacy of subjects participated in phase 1 trial to evaluate the safety and tolerability of autologous bone marrow-derived…
- Trial name
- NCT04495582
- Where
- South Korea
- Volunteers
- 8 people
- Sponsor
- Corestemchemon, Inc.
Advanced Solid Tumors
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
This study will test a Regeneron drug called REGN13089-M404-M2980 ("study drug") to see if it can help treat previously treated, advanced solid tumors (tumors that have grown and spread to different areas of the body).
- Trial name
- NCT07863024
- Testing
- REGN13089-M404-M2980
- Volunteers
- 320 people
- Sponsor
- Regeneron Pharmaceuticals
Myeloma
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
This is a 2 part study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of DS-3032b that can be given to patients with multiple…
- Trial name
- NCT02579824
- Testing
- DS-3032b
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated solid tumour for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit.
- Trial name
- NCT00744562
- Testing
- OMP-21M18
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Lung Cancer
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00098462
- Testing
- gefitinib, sirolimus
- Sponsor
- Jonsson Comprehensive Cancer Center
Lipoma
Deoxycholic Acid Injection for the Treatment of Superficial Lipomas
The purpose of this research is to compare the safety and effectiveness of 4 different concentrations of deoxycholic acid injection against a placebo in the treatment of superficial lipomas.
- Trial name
- NCT00422188
- Testing
- Deoxycholic Acid Injection
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Kythera Biopharmaceuticals
Cytomegalovirus Infections
Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
The purpose of the study is to assess the safety and tolerability of a 3-dose regimen of V160 administered by intramuscular (IM) injection in healthy Japanese male participants by cytomegalovirus (CMV) serostatus.
- Trial name
- NCT03840174
- Testing
- V160
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study of SPY002-091 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.
- Trial name
- NCT06672718
- Testing
- SPY002-091
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Spyre Therapeutics, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of anhydrovinblastine in treating patients who have…
- Trial name
- NCT00003882
- Testing
- anhydrovinblastine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Sensorineural Hearing Loss
FX-322 in Sensorineural Hearing Loss
This is a phase 1/2 study of FX-322 at two dose levels compared to placebo in male and female adults otherwise healthy with stable sensorineural hearing loss.
- Trial name
- NCT03616223
- Testing
- FX-322
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Frequency Therapeutics
Moderate to Severe Atopic Dermatitis
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
The study will be conducted to evaluate the safety and tolerability of SHR-1819 injection and describe the PK/PD/ADA and explore the clinical efficacy.
- Trial name
- NCT05197023
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
HIV-1, HIV Infections
Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers
Objectives: Safety and immunogenicity of MVA.HIVA vaccine in 20-week-old healthy Gambian infants born to HIV-1/2-uninfected mothers.
- Trial name
- PedVacc001 (NCT00982579)
- Testing
- MVA.HIVA
- Where
- The Gambia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medical Research Council
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
- Trial name
- NCT01661179
- Testing
- Vandetanib 300mg
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Cancer
A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours
This clinical trial is an open-label, single-centre, phase I study designed to investigate the safety and tolerability of a single infusion of autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ…
- Trial name
- LeY-CAR-T (NCT03851146)
- Testing
- LeY CAR T cells
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome
Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML
The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in…
- Trial name
- BRAMLIE (NCT07723703)
- Testing
- AMX-883, Posaconazole
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 54 people
- Sponsor
- Amphista Therapeutics Ltd
Peripheral T-Cell Lymphoma
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
This study will determine the maximum dose of KW-0761 administered intravenously that can be given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma(CTCL)and will see if it…
- Trial name
- NCT00888927
- Testing
- KW-0761
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Retinitis Pigmentosa
Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
The purpose of this study is to evaluate the short-term safety of a single intravitreal injection of autologous bone marrow stem cells in patients with retinitis pigmentosa.
- Trial name
- NCT01068561
- Testing
- intravitreal injection of autologous bone marrow stem cells
- Where
- Brazil
- Volunteers
- 5 people
- Sponsor
- University of Sao Paulo
Lung Cancer
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for…
- Trial name
- NCT00621361
- Testing
- AZD2171, Etoposide, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Safety,, Tolerability,
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD8848 in healthy subjects.
- Conditions
- Safety,, Tolerability,, Healthy Subjects
- Trial name
- NCT01818869
- Testing
- AZD8848
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
DM1, Myotonic Dystrophy 1
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
AOC 1001-CS1 is a randomized, double-blind, placebo-controlled, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple-doses of AOC 1001 Administered Intravenously to…
- Conditions
- DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1)
- Trial name
- MARINA (NCT05027269)
- Testing
- AOC 1001
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Avidity Biosciences, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.